Trending...
- NFL Midseason 2025: Who's for Real and Who's Faking It?
- Jonathan Malveaux Named Newest Member of Forbes Business Council
- PebblePad Announces Global Partnership with Inside Higher Ed and Times Higher Education
Substantial Funding Agreements, Debt Resolution and Successful Clinical Trial Progress Towards Accelerated Drug Approval
RADNOR, Pa. - PennZone -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"
In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.
More on The PennZone
The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.
NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.
NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.
The potential of these two NRXP therapies is monumental. Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes. Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.
The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.
It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.
More on The PennZone
Participation at New York Global Investment Conference
NRXP has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.
Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
NRXP has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.
To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"
In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.
More on The PennZone
- Schemawriter.ai launches WordPress plugin as industry leaders confirm - schema markup is critical
- 20 Million Financing to Accelerate Growth and Advance Digital Asset Strategy Secured for Super League (N A S D A Q: SLE)
- uCAR Trading Launches goldsilbermarkt.de, a New Online Shop for Precious Metals
- Webinar Announcement: Reputational Risk Management in Internal Investigations: Controlling the Narrative Before, During, and After a Crisis
- Taking on the Multi-Billion-Dollar Swipe Industry: AI Curates Who You Meet—IRL over brunch
The author notes:
"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.
NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.
NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.
The potential of these two NRXP therapies is monumental. Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes. Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.
The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.
It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.
More on The PennZone
- 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
- Cartwheel Signs Letter of Intent to License Clearsight Therapeutics' Novel Pink Eye Treatment for 2027 Portfolio Expansion
- Vet Maps Launches National Platform to Spotlight Veteran-Owned Businesses and Causes
- Diamond Wealth Advisors Experience the New York Stock Exchange and Ring the Closing Bell
- $114.6 Million in Revenues, Up 54%: Uni-Fuels Holdings (N A S D A Q: UFG) Accelerates Global Expansion Across Major Shipping Hubs as Demand Surges
Participation at New York Global Investment Conference
NRXP has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.
Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
NRXP has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.
To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on The PennZone
- Kaltra Offers Microchannel Condensers Optimized for Low-GWP Refrigerants R454B, R32, and R290
- Putting Your Roses to Bed for Winter in the Deep South - A Gentleman's Guide to Fall Rose Care
- Tens of Thousands Complete Course to Master Entire Bible, Including Revelation
- UK Financial Ltd Unveils The First ERC-3643 Security Token Born from a Meme: Introducing MayaCat Regulated Security Token (SMCAT) Successor to MayaCat
- Kaplan Morrell Law Firm Represents Former NHL Player in Workers' Compensation Case Drawing National Attention
- Local Lighting Experts Debut AI Christmas Decorator: Upload a Photo, Get Instant Professional Holiday Design-- Completely Free
- Surf Air Mobility (N Y S E: SRFM) Accelerates Regional Air Mobility Revolution with Electra Aero Partnership, Palantir Alliance, and Record Revenue
- Cybersecurity is Fast Becoming a Vital Issue for Protecting Personal Information and Portfolio Wealth
- 10 Essential Tips for Maximizing Value When Choosing Your Orlando Wedding Venue
- Americans Are Trading Offices for Beaches: How Business Ownership Enables the Ultimate Location Freedom
- Boston Industrial Solutions' Natron® DC Series Ink Has Had an Upgrade!
- Colony Ridge Proudly Supports the All Ears! 2025 Sporting Clays Tournament
- Jacob Emrani Nominated for LA Executive Award
- VIP Vacations Named One of Top Travel Agencies
- Kansas City Steak Company Shares the Return of Their Holiday Gift Box
- Dr. Jay A. Johannigman Delivers Lecture at the John R. Border Memorial Lectureship in Buffalo
- Powering the Next Frontier of the $1 Trillion Space Economy: Ascent Solar Technologies (N A S D A Q: ASTI)
- Taikan's T-V856S VMC Earns Prestigious 2025 Vogel Global Pioneer Award
- Flick Truck Accident Law Joins the Commercial Vehicle Safety Alliance to Strengthen Truck Safety Advocacy
- PebblePad Announces Global Partnership with Inside Higher Ed and Times Higher Education